Story

Sprout Social to Cut 20% of Workforce in Restructuring Plan

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Sprout Social to Cut 20% of Workforce in Restructuring Plan

Summary

The social media management company is laying off approximately 260 employees to streamline operations and increase investment in AI, expecting to incur up to $20 million in related charges.

Text size
Background

Sprout Social is reducing its workforce by approximately 20%, a move that will affect around 260 employees as part of a new restructuring plan. The company began notifying affected staff on Tuesday, according to an announcement.

Details of the Plan

The company's board of directors approved the restructuring on July 8, 2026. In a statement, Sprout Social said the plan is designed to streamline its organizational structure and align operational costs with its strategic priorities.

A key goal of the realignment is to facilitate ongoing investments in areas the company deems critical for growth, particularly its AI-powered social intelligence capabilities. The company expects to complete the restructuring process by the end of the third quarter of 2026, subject to local laws and consultation requirements.

Sample IUX Markets – In-articleAd

Financial Implications

Sprout Social estimates it will incur pre-tax restructuring charges between $18.0 million and $20.0 million. These charges are primarily composed of cash expenditures for employee severance payments and benefits.

The company expects to recognize the vast majority of these costs in the third quarter of 2026. For investors, this move signals a decisive effort to improve operational efficiency and reallocate capital towards high-growth technology, a strategy often viewed favorably by the market if it leads to improved long-term profitability.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST